Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003.
BACKGROUND
In Australia two acellular Bordetella pertussis vaccines have replaced the use of a whole cell vaccine. Both of the licensed acellular vaccines contain the following three components; pertussis toxoid, pertussis filamentous haemagglutinin and the 69 kDa pertactin adhesin. One vaccine also contains pertussis fimbriae 2 and 3. Various researchers have postulated that herd immunity due to high levels of pertussis vaccination might be influencing the makeup of endemic B. pertussis populations by selective pressure for strains possessing variants of these genes, in particular the pertactin gene type. Some publications have suggested that B. pertussis variants may be contributing to a reduced efficacy of the existing vaccines and a concomitant re-emergence of pertussis within vaccinated populations. This study was conducted to survey the pertactin and pertussis toxin subunit 1 types from B. pertussis isolates in Queensland, Australia following the introduction of acellular vaccines.


METHODS
Forty-six B. pertussis isolates recovered from Queensland patients between 1999 and 2003 were examined by both DNA sequencing and LightCycler real time PCR to determine their pertactin and pertussis toxin subunit 1 genotypes.


RESULTS
Pertactin typing showed that 38 isolates possessed the prn1 allele, 3 possessed the prn2 allele and 5 possessed the prn3 allele. All forty-six isolates possessed the pertussis toxin ptxS1A genotype. Amongst the circulating B. pertussis population in Queensland, 82.5% of the recovered clinical isolates therefore possessed the prn1/ptxS1A genotype.


CONCLUSIONS
The results of this study compared to historical research on Queensland isolates suggest that B. pertussis pertactin and pertussis toxin variants are not becoming more prevalent in Queensland since the introduction of the acellular vaccines. Current prevalences of pertactin variants are significantly different to that described in a number of other countries with high vaccine coverage. Relative paucity of recovered isolates compared to notified infections, due primarily to non culture based pertussis diagnostics is however a confounding factor in the assessment of variant prevalence.
Public Health Microbiology, Queensland Health Scientific Services, Brisbane, Australia. Shane_Byrne@health.qld.gov.au
Shane
S
Byrne
Andrew T
AT
Slack
D000293:Adolescent; D000328:Adult; D000483:Alleles; D001425:Bacterial Outer Membrane Proteins / Q000145:classification / Q000235:genetics*; D001886:Bordetella pertussis / Q000235:genetics*; D002648:Child; D002675:Child, Preschool; D005260:Female; D014644:Genetic Variation; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D037342:Pertussis Toxin / Q000145:classification / Q000235:genetics*; D010567:Pertussis Vaccine / Q000235:genetics; D011793:Queensland; D013997:Time Factors; D010566:Virulence Factors, Bordetella / Q000145:classification / Q000235:genetics*
D001425:Bacterial Outer Membrane Proteins; D010567:Pertussis Vaccine; D010566:Virulence Factors, Bordetella; C068929:pertactin; D037342:Pertussis Toxin